GlassScriptPhysician profile
Justin Cullifer
NPI 1396321113
$1,785.26
in general payments reported to CMS, 2019-2025
26 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what 89% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.64 · 2024: $303 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.36 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.38 | 2025 | Caplyta |
| Amgen INC. | $238.94 | 2025 | Evenity, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.65 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $152.85 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $96.02 | 2024-2025 | Unithroid |
| Otsuka America Pharmaceutical, INC. | $75.23 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $74.52 | 2024-2025 | Farxiga, Breztri |
| Radius Health, INC. | $70.62 | 2024-2025 | Tymlos |
| Corium, LLC | $67.73 | 2025 | Azstarys |
| Pfizer INC. | $55.37 | 2024-2025 | |
| Corcept Therapeutics | $51.85 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $46.20 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $40.50 | 2024-2025 | |
| Abbvie INC. | $34.13 | 2025 | |
| Lundbeck LLC | $32.26 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.24 | 2024 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $24.12 | 2024 | Gvoke Hypopen |
| Tris Pharma INC | $18.83 | 2025 | Dyanavel Xr |
| Viatris Specialty LLC | $18.17 | 2025 | Yupelri |
| Alkermes, INC. | $17.68 | 2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $17.64 | 2023 | Shingrix |
| Esperion Therapeutics, INC. | $16.60 | 2025 | Nexletol |
| Axsome Therapeutics, INC. | $15.80 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $15.00 | 2024 | Voquezna |
| Exact Sciences Corporation | $14.69 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $13.24 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Cullifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.